BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31531499)

  • 1. High-content screening Raman spectroscopy (HCS-RS) of panitumumab-exposed colorectal cancer cells.
    Mondol AS; El-Mashtoly SF; Frick T; Gerwert K; Popp J; Schie IW
    Analyst; 2019 Oct; 144(20):6098-6107. PubMed ID: 31531499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Throughput Screening Raman Spectroscopy Platform for Label-Free Cellomics.
    Schie IW; Rüger J; Mondol AS; Ramoji A; Neugebauer U; Krafft C; Popp J
    Anal Chem; 2018 Feb; 90(3):2023-2030. PubMed ID: 29286634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
    Pietrantonio F; Cremolini C; Aprile G; Lonardi S; Orlandi A; Mennitto A; Berenato R; Antoniotti C; Casagrande M; Marsico V; Marmorino F; Cardellino GG; Bergamo F; Tomasello G; Formica V; Longarini R; Giommoni E; Caporale M; Di Bartolomeo M; Loupakis F; de Braud F
    Oncologist; 2015 Nov; 20(11):1261-5. PubMed ID: 26446234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells.
    El-Mashtoly SF; Yosef HK; Petersen D; Mavarani L; Maghnouj A; Hahn S; Kötting C; Gerwert K
    Anal Chem; 2015 Jul; 87(14):7297-304. PubMed ID: 26075314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
    Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
    Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
    Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
    J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS
    J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of serum Raman spectroscopy between normal and colorectal cancer using selected parameters and regression-discriminant analysis.
    Li X; Yang T; Li S
    Appl Opt; 2012 Jul; 51(21):5038-43. PubMed ID: 22858942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging vs Nonimaging Raman Spectroscopy for High-Throughput Single-Cell Phenotyping.
    Hobro AJ; Pavillon N; Koike K; Sugiyama T; Umakoshi T; Verma P; Fujita K; Smith NI
    Anal Chem; 2024 May; 96(18):7047-7055. PubMed ID: 38653469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.
    Baba Y; Tamura T; Satoh Y; Gotou M; Sawada H; Ebara S; Shibuya K; Soeda J; Nakamura K
    Mol Oncol; 2017 Aug; 11(8):1065-1077. PubMed ID: 28486761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single cell Raman spectroscopy for cell sorting and imaging.
    Li M; Xu J; Romero-Gonzalez M; Banwart SA; Huang WE
    Curr Opin Biotechnol; 2012 Feb; 23(1):56-63. PubMed ID: 22138495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic evaluation of the biological variance within the Raman based colorectal tissue diagnostics.
    Vogler N; Bocklitz T; Subhi Salah F; Schmidt C; Bräuer R; Cui T; Mireskandari M; Greten FR; Schmitt M; Stallmach A; Petersen I; Popp J
    J Biophotonics; 2016 May; 9(5):533-41. PubMed ID: 26687775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of panitumumab for K-ras wild-type unresectable or recurrent colorectal cancer - a study focusing on first-line treatment].
    Mitomo S; Suto T; Umemura A; Ishida K; Kanno K; Takeda D; Fujita T; Otsuka K; Nitta H; Uesugi N; Sugai T; Wakabayashi G
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):731-5. PubMed ID: 25129084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimisation of wavelength modulated Raman spectroscopy: towards high throughput cell screening.
    Praveen BB; Mazilu M; Marchington RF; Herrington CS; Riches A; Dholakia K
    PLoS One; 2013; 8(6):e67211. PubMed ID: 23825643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual staining of colon cancer tissue by label-free Raman micro-spectroscopy.
    Petersen D; Mavarani L; Niedieker D; Freier E; Tannapfel A; Kötting C; Gerwert K; El-Mashtoly SF
    Analyst; 2017 Apr; 142(8):1207-1215. PubMed ID: 27840868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
    Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell Raman sorting.
    Li M; Boardman DG; Ward A; Huang WE
    Methods Mol Biol; 2014; 1096():147-53. PubMed ID: 24515367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Raman spectroscopic study of cell response to clinical doses of ionizing radiation.
    Harder SJ; Matthews Q; Isabelle M; Brolo AG; Lum JJ; Jirasek A
    Appl Spectrosc; 2015; 69(2):193-204. PubMed ID: 25588147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.